Capable is building a vertically integrated, AI-enabled deeptech platform to accelerate the discovery and development of peptide and nucleotide therapeutics. The company aims to counter human biological limitations—such as susceptibility to major diseases—by using frontier AI to design next-generation medicines and automated polymer synthesis to rapidly produce them. Its platform is designed to replicate and improve upon the success of blockbuster peptide drugs like Tirzepatide.
Funding
Funding not disclosed
Founders
Product
Problem
Humans are biologically constrained: we are susceptible to major illnesses like cancer and heart disease, and we spend a significant portion of our lives asleep or otherwise limited. Current drug discovery processes are slow and fail to fully leverage frontier AI capabilities, leaving significant human potential and therapeutic opportunities untapped.
Solution
Capable is building a vertically integrated, AI-enabled deeptech platform that combines frontier intelligence with automated polymer synthesis to rapidly explore and unlock new human capabilities. The platform leverages advanced AI models to design novel peptide and nucleotide therapeutics, then uses automated solid-phase peptide synthesis (SPPS) to manufacture these compounds quickly and precisely. By integrating AI-driven design with rapid, automated production, Capable aims to streamline the entire pipeline from computational discovery to physical therapeutic, with the goal of producing the next generation of high-impact drugs in a fraction of the traditional time.
Target Audience
Capable's primary customers are pharmaceutical and biotechnology companies seeking to accelerate peptide- and nucleotide-based drug discovery and development, as well as research institutions focused on expanding human performance and longevity.
Features
- AI-driven therapeutic design platform for discovering novel peptide and nucleotide drug candidates
- Automated solid-phase peptide synthesis (SPPS) enabling rapid, scalable polymer production
- Vertically integrated workflow that connects AI models directly to physical synthesis and testing
- Focus on peptide therapeutics, a class validated by top-selling drugs such as Tirzepatide
- Deeptech infrastructure designed to unlock new human capabilities beyond treating disease